Evolving Care Strategies in Newly Diagnosed HL: Emerging Therapies and the Changing Role of the Oncology Nurse Webcast

A Complimentary Live Simulcast—Developed by Oncology Nurses for Oncology Nurses

Join us for this simulcast and earn 1.0 credit hour of continuing education.

Friday, October 26, 2018
12:45 - 1:45 PM EDT pm – Symposium
DoubleTree Tampa Airport Hotel

This symposium is a satellite session and not part of the official 2018 ONS Regional Meeting.

Program Overview
New agents, new indications, and new and emerging therapies are changing the treatment paradigms and care of patients with newly diagnosed Hodgkin lymphoma. This symposium will take a closer look at these changes and their impact to nursing care. Our presenters will provide an overview of the therapeutic treatment options and their known side-effect profiles which, if left unmanaged, could impact the overall progress and quality of life for patients. This activity will include presentations from our expert faculty on best strategies to employ in recognizing, treating, and long-term management of adverse events. We encourage you to join in on an interactive discussion with faculty regarding some of your day-to-day challenges in caring for and providing education to your Hodgkin lymphoma patients and their caregivers.

Target Audience
This activity is designed for multidisciplinary healthcare providers in the community setting, including oncology nurses and other allied healthcare professionals who provide care to patients with Hodgkin lymphoma.

Learning Objectives
Upon completion of this educational activity, participants should be able to:
  • Outline potential treatment strategies for newly diagnosed Hodgkin lymphoma (HL) patients, identifying patient- and disease-related factors that should be considered in selecting the most appropriate therapy for each individual
  • Correlate efficacy and safety data of agents that have been recently approved for treatment of newly diagnosed HL patients with the most appropriate patient type for each
  • Describe the potential impact of treatment-related adverse events (AEs) in newly diagnosed HL patients, and outline proactive management strategies for monitoring and treating these AEs
  • Apply strategies for educating and communicating with newly diagnosed HL patients that will support improved patient-centric care and optimized outcomes
Amy L. Goodrich, RN, MSN, CRNP-AC Amy L. Goodrich, RN, MSN, CRNP-AC
Nurse Practitioner
Hematologic Malignancies Program
The Sidney Kimmel Cancer Center at Johns Hopkins
Research Associate
The Johns Hopkins School of Medicine
Baltimore, Maryland
Mollie E. Moran, MSN, CNP, AOCN-P Mollie E. Moran, MSN, CNP, AOCNP
Oncology Nurse Practitioner
Hematologic Malignancies Division
James Cancer Hospital and Solove Research Institute
The Ohio State University
Columbus, Ohio


*all times are listed in Eastern Time (ET)*

12:30 pm Login

12:45 pm – 12:55 pm Welcome and Overview
  • Updates in the Standard of Care for First-Line Therapy in Advanced Hodgkin Lymphoma: The Critical Role of the Oncology Nurse in Meeting Patients’ Needs
12:55 pm – 1:15 pm A New Era in HL: How New Agents, New Indications, and Emerging Therapies Are Changing Treatment Paradigms
  • Advances in Treating Newly Diagnosed HL: A Look at Advanced-Stage Disease
  • New and Emerging Agents Driving Treatment Change
1:15 pm – 1:35 pm Nursing Care and Challenges: Before, During, and After Treatment
  • Adverse Events versus Disease Symptoms: Differentiating Between the Two
  • Assessing the Patients’ Adverse Events and Their Impact on Patients’ Quality of Life
  • The Role of Patient Education and the Positive Impact of Shared Decision Making
1:35 pm – 1:45 pm Panel Discussion/Audience Questions

MediCom Worldwide, Inc. NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 18-039-087

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Americans with Disabilities Act/Special Needs
MediCom Worldwide, Inc. is committed to equality of educational opportunity and does not discriminate against applicants, students, or employees on the basis of race, color, religion, sex, national origin, age, disability, veterans status, or sexual orientation.

Instructions for Participation and Credit
There are no fees for participating in this activity. In order to receive credit, all participants must complete the Activity Evaluation Form following the activity. Partial credit will not be awarded for this activity. CNE/CE certificates will be emailed 4 weeks following receipt of a completed, qualified form.

If you have any questions regarding this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, ext. 128 or email lisa@medicaled.com

Provided by
MediCom Worldwide, Inc.
Supported by an educational grant from Seattle Genetics, Inc.